Jonathan Alspaugh - Jun 22, 2023 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (AGLE)

Role
President and CFO
Signature
/s/ Jonathan Alspaugh
Stock symbol
AGLE
Transactions as of
Jun 22, 2023
Transactions value $
$0
Form type
4
Date filed
6/30/2023, 04:34 PM
Previous filing
Feb 24, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Employee Stock Option (right to buy) Award $0 +19.8M $0.00 19.8M Jun 22, 2023 Common Stock 19.8M $0.30 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder.
F2 The stock option vests and becomes exercisable in 48 equal monthly installments beginning on July 22, 2023, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.